Phospho-ceramide analog-1 (PCERA-1) has been described as a potent in vivo suppressor of the pro-inflammatory
cytokine tumor necrosis factor alpha (
TNFalpha), and thus as a putative
drug for the treatment of inflammatory diseases. However, the in vivo cell target of
PCERA-1 has not been identified, and its in vivo effect on secretion of other relevant
cytokines has not been reported. We have previously shown that
PCERA-1 suppresses
lipopolysaccharide (LPS)-induced
TNFalpha production in RAW264.7 macrophages in vitro. We therefore hypothesized that
PCERA-1 targets
TNFalpha production by primary macrophages. In this study we thus investigated the effect of
PCERA-1 on LPS-induced release of
TNFalpha,
interleukin (IL)-10 and
IL-12p40, in vivo, and ex vivo. We found that
PCERA-1 suppressed production of the pro-inflammatory
cytokines,
TNFalpha and
IL-12p40, and increased production of the anti-inflammatory
cytokine,
IL-10, in LPS-challenged mice, and in primary peritoneal macrophages as well as bone marrow-derived macrophages (BMDM) stimulated with LPS and
interferon (IFN)-gamma. These activities of
PCERA-1 were independent of each other. In contrast, PCREA-1 only slightly affected
TNFalpha production in the whole blood assay, where LPS-induced
cytokines are mainly produced by monocytes. Moreover, isolated blood monocytes were inert to
PCERA-1, but acquired responsiveness to
PCERA-1 upon
macrophage colony stimulating factor (
M-CSF)-induced differentiation into macrophages. Pharmacokinetic analysis in mice showed that while the volume of distribution of
PCERA-1 is low, the
drug was rapidly exchanged between the peritoneum and the systemic circulation. Together, these results suggest that sensitivity to
PCERA-1 increases upon differentiation of blood monocytes into tissue macrophages, and imply a mechanistic role for peritoneal macrophages in the in vivo anti-inflammatory activity of
PCERA-1. Finally, we show that the mechanism of activity of
PCERA-1 and
prostaglandin E2 (
PGE2) is distinct, and that
PCERA-1 signaling is not mediated by EP2, a
PGE2 receptor which is also activated by oxidized
phospholipids. The independent and reciprocal modulation of production of
TNFalpha and
IL-12p40, vs.
IL-10, suggests that
PCERA-1 may be a candidate
drug for the treatment of
inflammation-linked diseases.